Protease inhibitors as immunomodulatory drugs for HIV infection.
More than 20 drugs from four therapeutic drug classes are widely available for the management of human immunodeficiency virus (HIV) infection, with promising drugs from two new drug classes expected to be approved by the US Food and Drug Administration (FDA) in mid-to-late 2007 (Table 1). When used in combination, these drugs can lead to durable and perhaps indefinite suppression of viral replication.
Deeks
S G
SG
University of California, San Francisco, California, USA. sdeeks@php.ucsf.edu
D023241:Antiretroviral Therapy, Highly Active; D017209:Apoptosis / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D017320:HIV Protease Inhibitors; D007155:Immunologic Factors